Abstract: A subject-matter of the present invention is a cosmetic composition expanded in volume, in the form of an oil-in-water emulsion, comprising an internal fatty phase and an external aqueous phase comprising at least one inulin modified by hydrophobic chains and at least two gelling agents for the aqueous phase, one of the two gelling agents being chosen from unmodified clays, in particular montmorillonites, hectorites, smectites, bentones or laponites, or cellulose polymers, such as hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose and quaternized cellulose derivatives, and the other gelling agent being chosen from gums arabic, guar gum, xanthan derivatives, karaya gum or locust bean gum, the said internal fatty phase being present in a content ranging from 5 to 50% by weight.

Abstract: Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator.

Abstract: In one embodiment, a personal-care composition in the form of a water-in-oil emulsion comprises at least about 10% of a non-polar silicone oil; from about 0.1% to about 10% of a first oil-soluble solid sunscreen; and from about 0.1% to about 10% of a second oil-soluble solid sunscreen. The weight ratio of the first sunscreen to the second sunscreen may be from about 0.8 to about 2.0, or from about 1.0 to about 1.5. The first sunscreen may be oxybenzone. The second sunscreen may be avobenzone. The composition may further comprise a skin-care active selected from the group consisting of a vitamin B3 compound, a sugar amine, a peptide, a hexamidine compound, and combinations thereof. In another embodiment, the invention relates to a method for improving the solubility of a second oil-soluble solid sunscreen in the oil phase of a water-in oil emulsion.

Abstract: Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide compositions and methods suitable for modulation of at least one of cellular membrane potential and cellular membrane conductivity. Additional aspects provide compositions and methods suitable for modulating intracellular signal transduction, including modulation of at least one of membrane structure, membrane potential or membrane conductivity, membrane proteins or receptors, ion channels, and calcium dependant cellular messaging systems, comprising use of the inventive electrokinetically altered solutions to impart electrochemical and/or conformational changes in membranous structures (e.g.

Abstract: The present invention relates to methods for sterilization of dispersions of one or more nanoparticulate active agents via gamma irradiation.

Abstract: In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously; consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.

Abstract: Compositions and methods for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are compositions and methods for treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells.

Abstract: Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide and at least one metal oxide. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one metal oxide. Still, other alternative embodiment pesticide compositions exhibiting enhanced pesticidal activity are disclosed.

Abstract: Hypoallergenic metal amino acid chelate compositions, hypoallergenic formulations containing hypoallergenic metal amino acid chelates, methods of preparing hypoallergenic metal amino acid chelate, and methods of administering hypoallergenic metal amino acid chelates are provided. Specifically, the present invention provides metal amino acid chelates that are substantially free of allergens such that administration of the metal amino acid chelates to a subject in an effective amount to cause a medicinal or nutritional result does not produce a discernable adverse allergic reaction. The metal amino acid chelates can include chelates having a naturally occurring amino acid to metal molar ratio of from about 1:1 to 4:1.

Abstract: The present invention relates to a visual indicating device and an article for controlling odors, in particular foot, garbage, basement, cooking, pet, tobacco, feces and urine odors. The article comprises a visual indicating agent that is color sensitive to the odor, and optionally, an odor absorbing agent. The visual indicating agent changes color when the article has been exposed to a sufficient amount of odor to saturate the article. The indicating agent may be applied in differing concentrations to two or more zones so as to indicate to a user of the article how much of the odor absorbing capacity has been used, or conversely, how much of the odor absorbing capacity remains. Suitable visual indicating agents that change color in response to odors are also described. The article for controlling odors may be a disposable odor absorbing sheet, air freshening product, diaper, undergarment pad, face mask, air filtration device, sanitary napkin, tampon, panty shield or incontinence pad.

Abstract: An object of the present invention is to provide a scavenger of in vivo harmful reactive oxygen species and/or free radicals, which is capable of effectively reducing the concentrations of in vivo reactive oxygen species and/or free radicals and exhibiting given effects such as the suppression of aging process, the prevention of geriatric or lifestyle-related disease, health promotion, and the inhibition of oxidative stress by virtue of this reduction in the concentrations of reactive oxygen species and/or free radicals. The scavenger of in vivo harmful reactive oxygen species and/or free radicals of the present invention comprises a liquid or gas comprising at least a hydrogen molecule. This medium may further comprise an oxygen molecule. Furthermore, this medium may comprise water or an aqueous solution or may be a gas. The scavenger of reactive oxygen species and/or free radicals can be used in the treatment or prevention of a disorder attributed to reactive oxygen species and/or free radicals.

Abstract: This application provides methods and compositions for modulating and/or depleting CD200 positive cells.

Abstract: Disclosed are infant formulas and corresponding methods of using them to promote retinal health and vision development in infants. The formulas, which are free of egg phospholipids and comprise fat, protein, carbohydrate, vitamins, and minerals, including docosahexaenoic acid and, on a ready-to-feed basis, at least about 50 mcg/liter of lutein, wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1:2 to about 10:1. The formulas are also believed to be especially useful in reducing the risk of retinopathy of prematurity in preterm infants.

Abstract: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.

Abstract: Provided are oral compositions and devices comprising an active agent that is one of chlorine dioxide-generating components, a chlorine dioxide-containing solution, and combinations thereof.

Abstract: A solution containing a C70 cyclodextrin complex and a solution containing a lipid that is capable of forming a liposome are mixed together at a temperature in a range of 10° C. to 45° C. This produces a C70-incorporated liposome which keeps a physical property that the C70 fullerene originally has, and is stably solubilized in a polar solvent. Hence, the present invention provides a C70-incorporated liposome which keeps a physical property that the C70 fullerene originally has, and which is stably solubilized in a polar solvent, a production method of the same, and a use of the same.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined composition for simultaneous, separate or sequential use for treating ischemia. The present invention also relates to the use of at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, for the preparation of a combined pharmaceutical composition for treating ischemia.

Abstract: Animal carcasses are disinfected by applying to the surface of the animal carcass an acidified solution of chlorine dioxide. The chlorine dioxide solution should have a pH of about 2-3 and a concentration of 1-100 ppm. The contact time for the solution onto the carcass surface should be from about 5 seconds to about 60 seconds.

Abstract: The present invention relates to new thienobenzodiazepine modulators of D1 receptors, D2 receptors, and/or 5-HT2 receptors, pharmaceutical compositions thereof, and methods of use thereof.

Abstract: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.

Abstract: The present invention relates to the use of magnets in the treatment of cancer wherein the magnetic product comprises a magnet having positive and negative poles, the magnet having an additional metallic directional which distorts the magnetic field distribution around the magnet so as to attenuate the magnetic field in the vicinity of the positive pole of the magnet. The invention also relates to methods of treatment using those magnets.

Abstract: A device for treating a skin condition is provided. The device comprises a delivery system for administering a composition to the skin disorder. The delivery system includes an electrode for delivering a composition to the skin of a person and a counter electrode. The device also includes a drainage system which includes a channel for removing material from a person's skin and a pump in communication with the channel The device further includes a control system for powering and controlling the electrode system.

Abstract: A method for preparing a suspension of LDH particles comprises the steps of preparing LDH precipitates by coprecipitation to form a mixture of LDH precipitates and solution; separating the LDH precipitates from the solution; washing the LDH precipitates to remove residual ions; mixing the LDH precipitates with water; and subjecting the mixture of LDH particles and water from step (d) to a hydrothermal treatment step by heating to a temperature of from greater than 80° C. to 150° C. for a period of about 1 hour to about 144 hours to form a well dispersed suspension of LDH particles in water.

Abstract: A method for enlarging a peripheral vein so as to facilitate venipuncture of the vein by topically applying a vasodilator salt compound to skin overlying the vein and permitting the salt compound to cause the vein to enlarge by causing the vein to fill with blood.

Abstract: The invention provides a total enteral nutritious composition containing proteins, sugars, fats, minerals and vitamins, which improves serum albumin and ameliorates bedsores. The total enteral nutritious composition has a zinc/copper weight ratio of 10-25, and a zinc content of 1.5 mg or greater, a copper content of 0.075-0.15 mg, a sodium content of at least 185 mg, a vitamin B1 content of at least 0.30 mg, a vitamin B2 content of at least 0.25 mg and a protein content of at least 4.0 g, per 100 kcal of the composition. Preferably it has a protein content of at least 5.0 g, a vitamin B6 content of at least 0.30 mg, a biotin content of at least 1.0 ?g, a vitamin B12 content of at least 0.20 ?g, a folic acid content of at least 20 ?g, a ?-carotene content of at least 100 ?g and a vitamin C content of at least 10 mg. Medium-chain fatty acid oils preferably constitute 35% by weight of the fats of the fat source, per 100 kcal of the composition. The preferred composition viscosity is 6-18 mPa·s (25° C.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: The present invention is for extremely pure solutions of chlorine dioxide, methods for making such solutions and to compositions and methods for storing, shipping and using such solutions. Generally, the chlorine dioxide solutions of the invention are aqueous solutions containing about 2500 ppm or less of total impurities. The chlorine dioxide solution can be prepared by passing dilute highly pure chlorine gas through a bed of substantially solid sodium chlorite and contacting the resulting chlorine dioxide gas with a liquid.

Abstract: The present invention provides a new pharmacologic-functioning water demonstrating pharmacologic function without any side effects, and usage of the same. The pharmacologic-functioning water, which demonstrates pharmacologic function without any side effects and includes antioxidant-functioning water as an active principle containing hydrogen-dissolved water, which is made up of molecular hydrogen used as a substrate that is included in raw water, and a precious metal colloid, which is included in the hydrogen-dissolved water and catalyzes the breaking reaction of the molecular hydrogen into a product of atomic hydrogen, is used for preventing and/or treating diseases.

Abstract: A method for producing a purified, stable, compressible gas from an aqueous fluid. The gas is suitable for a variety of uses and may also be infused into water which itself is useful for a variety of purposes.

Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurised canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimising the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.

Abstract: The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles.

Abstract: The method disclosed herein entails treating a person, with sickle cell disease and who is suffering a pain crisis, with an effective amount of xenon, which alleviates the pain. Inhalation of xenon at subanesthetic concentrations has significant analgesic properties, which are mechanistically independent from the opioid receptor system. Inhaled xenon diminishes the propensity of sickle hemoglobin to aggregate by occupying critical internal cavities within the sickle hemoglobin molecule. Decreased hemoglobin polymerization and red blood cell sickling is beneficial during acute crisis and reduces the high incidence of sickle cell related complications after surgery.

Abstract: The present invention relates to pigments, comprising a plate-like substrate of perlite, and (a) a dielectric material, especially a metal oxide, having a high index of refraction; and/or (a) a metal layer, especially a thin semi-transparent metal layer; a process for their production and their use in paints, ink-jet printing, for dyeing textiles, for pigmenting coatings (paints), printing inks, plastics, cosmetics, glazes for ceramics and glass.

Abstract: The present invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of virus-based diseases of the respiratory tract.

Abstract: The present invention relates to electrochemically treated water, obtainable by means of a method that is characterized by the following steps: a) electrolyzing water and b) reducing the concentrations of the oxidants created in step a). The electrochemically treated water obtained in this manner is characterized by a disinfecting effect on bacteria, bacterial spores, fungi, fungal spores, viruses, prions, or mixtures thereof. The invention further relates to water, characterized in that the same has a disinfecting effect on bacteria, bacterial spores, fungi, fungal spores, viruses, algae, prions, or mixtures thereof, that it is substantially free of disinfection agents with the exception of the oxidants related to the disinfection agents, and that it has a total concentration of oxidants of less than 20 ppm.

Abstract: A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue.

Abstract: Disclosed is an antimicrobial carbon black dispersion which exhibits excellent dispersant properties and also inhibits microbial contamination when used in consumer products such as cosmetic formulations. Also disclosed are methods for producing and using the antimicrobial carbon black dispersion.

Abstract: The present invention relates to a method for producing a device comprising the steps of (a) providing a solution comprising dissolved osteoinductive protein, (b) contacting the solution of the preceding step with a carrier containing a surface of metal or a metal alloy, (c) allowing coating of the surface of said carrier with said dissolved protein and (d) drying of the coated carrier obtained in step (c) wherein steps (b) to (d) are carried out under a reduced concentration of oxygen. The invention also encompasses a device obtainable by the method of the present invention. Moreover, the present invention relates to a pharmaceutical composition comprising the said device and to the use of the device for the preparation of a pharmaceutical composition to be used for an accelerated osseointegration and new bone formation. Finally, the present invention relates to a kit comprising the device of the present invention.

Abstract: Biocompatible materials that have the ability to release nitric oxide (NO) in situ at the surface-blood interface when in contact with blood. The materials which may be polymers (e.g., polyurethane, poly(vinyl chloride), silicone rubbers), metals, such as stainless steel, carbon, and the like are provided with biocatalysts or biomimetic catalysts on their surface that have nitrite, nitrate, and/or nitrosothiol-reducing capability. Illustratively, the catalysts are adsorbed or immobilized at the surface of the material. The catalysts can act on endogenous nitrite, nitrate, or nitrosothiols within the blood creating a local increase in the NO levels at the surface of the material. An illustrative enzymatic biocatalyst is mammalian xanthine oxidase. In another illustrative embodiment, a biomimetic catalyst is a copper (Cu(II)-ligand complex, e.g. dibenzo[e,k]-2,3,8,9-tetraphenyl-1,4,7,10-tetraaza-cyclododeca-1,3,7,9-tetraene. In some cases, lipophilic salts of nitrite/nitrate (e.g.

Abstract: A composition that generates and releases a biocidal solution comprising at least chlorine dioxide is presented. The composition comprises reactants capable of in-situ generation of chlorine dioxide, and a gelling agent that slows the rate of dissolution of the reactants, thereby increasing yield and providing a controlled release of biocidal solution. The compositions of the invention show improved environmental stability which can reduce the cost of packaging. The controlled release allows the use in multi-tablet chemical dispensers which may otherwise induce potentially explosive conditions or allow rapid release of the biocidal solution thereby inducing a spike in chemical concentration rather than a sustained release.

Abstract: An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants using materials derived from bactericidal metals wherein one metal is silver. The candidate bactericidal metal is preferably introduced in metallic, nanocrystalline, salt form, chelated form, or otherwise coupled form. Metal atoms, ions, molecules, clusters, or particles in concentrations between 0.001 to 100,000 parts per million (ppm) may be employed, wherein the preferred concentration of silver is sufficient to suppress bacterial viability. The bactericidal principle is preferably introduced to the plant by injection, ballistic insertion, pneumatic insertion, mechanical insertion, manual insertion, root application, aerosolization or spray in order to effect the treatment and prevention of systemic plant infections by bacterial agents of disease or reduced productivity.

Abstract: A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material comprising about 68% to about 99%, by weight, of the microparticle delivery system. Compositions containing the microparticle delivery system, and methods of manufacturing the microparticle delivery system, also are disclosed.

Abstract: A method for reducing odor is provided. The method comprises forming a coordination complex between a transition metal and a polydentate compound, and contacting the coordinated complex with an odorous compound. The transition metal provides one or more active sites for capturing the odorous compound. In some embodiments, the polydentate compound may be a polyalkylimine, such as polyethyleneimine, polypropyleneimine, or a dendrimer thereof.

Abstract: The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.

Abstract: Provided is a new use of Brown's gas, more particularly, to the use of Brown's gas for the treatment of diseases in mammals and a Brown's gas supply apparatus therefor. It is based on the assumption that the Brown's gas is a medium capable of directly supplying moisture (special form of water according to the third theory of Brown's gas) to many regions of the body via skin, etc. Various effects of the Brown's gas on the body have been demonstrated. In particular, provided is a new use of the Brown's gas for treatment or alleviation of the symptoms of a lesion in a lesional tissue, cell, or organ of a mammal. Provided is also a simple and inexpensive Brown's gas supply apparatus for supplying pure Brown's gas suitable to be applied to the human body.

Abstract: A process is disclosed for preparing polynuclear microcapsules by polymerizing an alkoxysilane at the oil/water interface of a multiple phase emulsion to form a suspension of polynuclear microcapsules. Also disclosed are polynuclear micro-capsules optionally comprising a hydrophilic active and uses thereof.

Abstract: The present invention relates to a method for arresting, protecting and/or preserving an organ which includes administering effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) local anaesthetic to a subject in need thereof. The present invention also relates to a method for arresting, protecting and/or preserving an organ which comprises adding a composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic to the organ. The present invention further provides a pharmaceutical or veterinary composition which includes effective amounts of (i) a potassium channel opener or agonist and/or an adenosine receptor agonist and (ii) a local anaesthetic.

Abstract: A composition comprising mineral water and a chelating agent present in an amount sufficient to maintain all of the minerals in the water in solution. The mineral water is preferably obtained from Mount Clemens, Mich., US, and is preferably chelated with an ammonium and/or a sodium salt of an acid selected from the group consisting of ethylenediaminetetraacetic acid, nitrilotetraacetic acid, ?-alaninediacetic acid, ethylenediaminosuccinic acid, aminotrimethylenephosphoric acid, serinediaacetic acid, asparaginediacetic acid, methylgylcinediacetic acid and mixtures thereof. The resultant chelated mineral water may be combined with a cosmetically acceptable skin-conditioning agent and a cosmetically acceptable topical carrier, thereby resulting in a cosmetic composition that will confer beneficial effects on the skin, e.g., softening, hydrating and healing effects.

Abstract: The invention relates to a method for preparing a nanocomposite material by simultaneous vapour phase chemical deposition and vacuum injection of nanoparticles and to the materials and nanoparticles obtained thus and the application thereof.

Abstract: Methods and compositions for diagnosis and treatment of neurodegenerative disorders are disclosed. The methods and compositions apply the discovery of the correlation between an hGDH2 gene polymorphism and the occurrence of atypical Parkinson's Disease.